**List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse**), **31.03.2017**

**Dated 6 January 2017**

**NOTIFICATION**

2017 starts with good news concerning the registration and further development of our product Tabex. The buyer of the share of Sopharma AD in Extab – Achieve – is undertaking a merger with another strong player in the development and registration of innovative medicines – Oncogenex, a publicly traded company on NASDAQ (<http://in.reuters.com/article/idINFWN1EV0QP>). The procedure is expected to be completed by mid 2017 subject to approval from the US FSC. Sopharma AD will own approximately 3.5% in the newly created company, which will aim at filing the IND for Tabex in 2017.

Apart from the work on Tabex, the new company is also active in the development of other medicines, including one to facilitate the process of treating certain types of cancer.

**Dated 9 January 2017**

**NOTIFICATION**

Sopharma AD hereby notifies that the revenues from sales for 2016 decrease with 5% compared to 2015, including 2% decrease in domestic sales mainly due to the overall market price erosion (for the same period the company has a 7% increase in sales in packages) and a 6% decrease in export sales.

“In the past few months we see some signs for economic and political stabilization in Russia, which give us certain security for the results of 2017. We are optimistic for the trend of recovery of the sales in the Ukraine. After the restructuring of our export activities our local teams work systematically for the increase of the results on a number of markets like Poland, Belarus, Latvia, etc. We are very proud with the successful registrations of new products which we are yet to develop. An excellent example is Tuspan – the coughing syrup, which will be available on a number of European markets even this year in case of successful and timely procedures. This year started with a long-awaited news concerning our project of registration of our product Tabex in the USA. In case a restructuring takes place between Achieve and Oncogenex (our remaining shares in the capital of Extab will be transformed in shares in Achieve in case of such restructuring) there will be two advantages for us: first, the new joint team of the two companies will have a much bigger chance of a successful registration of Tabex and second, “Sopharma” AD will become a shareholder in a public company traded on NASDAQ.”, says Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors, “Sopharma” AD.

**Dated 2 February 2017**

**NOTIFICATION**

Sopharma AD announces that on 31 January, 2017 in accordance with art. 262e and the following from the Commercial Code Medica AD and Sopharma AD signed a contract for transformation through merger of Medica AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0.9486, meaning that one share of Medica AD will be exchanged for 0.9486 shares of Sopharma AD. The companies have hired the services of certified appraisers whose report is a necessary prerequisite for the filing of the documents for transformation with the FSC. As of this moment the deputy Chairman “Investment Supervision” has not issued an approval in accordance with art. 124 from the LPOS of the transformation contract, of the reports of the BoD according to art. 262k from the Commercial code and the report of the appraiser under art. 262o from the Commercial Code.

**Dated 3 February 2017**

**NOTIFICATION**

For the first month of this year, revenues from sales decreased by 4% compared to the same period of 2015, including 5% decrease of domestic sales and 4% decrease of export sales.

**Dated 13 February 2017**

**NOTIFICATION**

Sopharma AD (the “Company”) notifies that on 13 February 2017 the Contract for merger, as well as reports of the management bodies of the companies involved in the transformation of the company under art. 262i of the CA and the report of the examiner under art. 262m of the CA for transformation through merger between Sopharma AD, Sofia, UIC 831902088 and Medica AD, Kazanluk, UIC 000000993 were filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA). As a result of the merger, all assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD shall be terminated without liquidation.

As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.9486 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.

**Dated 27 February 2017**

**NOTIFICATION**

Sopharma AD announces that the Competition Council of The Republic of Moldova allows the acquisition of over 51% of RAP Pharma International SRL by Sopharma AD.

**Dated 7 March 2017**

**NOTIFICATION**

For the first two months of this year, revenues from sales increased by 8% compared to the same period of 2016, including 5% decrease of domestic sales and 16% increase of export sales.

“We are very pleased with the results on the Russian market from the begining of this year and the trend is strenghteining in February reaching 40% increase in export sales.

We are hopeful also with regards to the registration of our product Tabex in the USA. After the news about the merger of Achieve and OncoGenex the good news continue. You can read more abou the cooperation of Achieve with NIH here: [www.oncogenex.com](http://www.oncogenex.com).

The preliminary consolidated report of Sopharma Group for 2016 shows that even though the period was relatively difficult on our foreign markets, we still managed to reach a satisfactory EBITDA of 70 million BGN and a net profit of a little bit more than 50 million BGN. Analysis of the main indicators shows improved profitability due to optimization of main expenses and in the light of a maximum market price of a bit over 3 BGN for the year P/E is 8.31 and ROE is 10.9% compared to 5.3% for 2015.”, says Mr. Ognian Donev, PhD, CEO and Chairman of the Board of directors of Sopharma AD.

**Dated 9 March 2017**

**NOTIFICATION**

Sopharma AD announces that Sopharma AD received a final prohibition from the Bulgarian Financial Supervision Commission (FSC) to extend a tender offering to the shareholders of Unipharm AD. Sopharma AD is preparing a new tender offering which reflects the comments of the FSC.

**Dated 21 March 2017**

**NOTIFICATION**

Sopharma AD (the “Company”) notifies that on 20 March 2017 Sopharma AD, Sofia, UIC 831902088 and Medica AD, Sofia, UIC 000000993 signed an annex to the Contract for transformation through merger reflecting the comments by the FSC. All documents will be filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA) after an independent certified evaluator prepares a report.

As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.8831 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.